Back to All Events

Oncologic Drugs Advisory Committee

On Wednesday, March 29, 2017, the Oncologic Drugs Advisory Committee (ODAC) unanimously supported, by a vote of 11-Yes to 0-No, with no abstentions, the safety and efficacy of rituximab/hyaluronidase injection for subcutaneous use, by Genentech, Inc. (Genentech), to treat patients with certain types of lymphoma and leukemia.

The goal date for the FDA to decide on approval (the PDUFA date) is June 26, 2017.